With 5 streams of end-to-end content spanning discovery, preclinical and translation, clinical lessons, process and analytical development, and manufacturing and supply chain: the 2026 agenda has been infused with trailblazing design, development, and production innovations to overcome patient resistance mechanisms and push ADCs to earlier line oncology treatments.
Uniting 800+ senior European ADC decision-makers across biopharma, clinicians, service providers, investors, and regulators, World ADC London is proud to bring the community together to kick off 2026 and shape the future of ADC development.
